PHAT — Phathom Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $537.25m
- $600.63m
- $0.68m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0.682 |
Cost of Revenue | |||||
Gross Profit | — | — | — | — | 0.515 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 106 | 126 | 137 | 172 | 168 |
Operating Profit | -106 | -126 | -137 | -172 | -167 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -255 | -129 | -144 | -198 | -202 |
Net Income After Taxes | -255 | -129 | -144 | -198 | -202 |
Net Income Before Extraordinary Items | |||||
Net Income | -255 | -129 | -144 | -198 | -202 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -255 | -129 | -144 | -198 | -202 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -10.3 | -3.88 | -4.65 | -5.05 | -3.93 |